A61K 31/17
Having the group >n—c—n< or >n—c—n<
Official title: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
A61K31/17 (Having the group >n—c—n< or >n—c—n<) appears on 1,075 US grants and 1,761 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,075
- Published applications
- 1,761
- Assignees
- 899
- Inventors
- 3,504
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 9 | 0 |
| 1978 | 3 | 0 |
| 1979 | 7 | 0 |
| 1980 | 8 | 0 |
| 1981 | 8 | 0 |
| 1982 | 7 | 0 |
| 1983 | 5 | 0 |
| 1984 | 10 | 0 |
| 1985 | 2 | 0 |
| 1986 | 10 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 8 | 0 |
| 1991 | 3 | 0 |
| 1992 | 7 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 10 | 0 |
| 1996 | 15 | 0 |
| 1997 | 35 | 0 |
| 1998 | 25 | 0 |
| 1999 | 22 | 0 |
| 2000 | 19 | 0 |
| 2001 | 27 | 8 |
| 2002 | 22 | 47 |
| 2003 | 30 | 69 |
| 2004 | 13 | 50 |
| 2005 | 11 | 73 |
| 2006 | 16 | 83 |
| 2007 | 12 | 48 |
| 2008 | 13 | 56 |
| 2009 | 16 | 49 |
| 2010 | 21 | 64 |
| 2011 | 25 | 55 |
| 2012 | 31 | 56 |
| 2013 | 38 | 66 |
| 2014 | 55 | 63 |
| 2015 | 35 | 75 |
| 2016 | 45 | 70 |
| 2017 | 48 | 98 |
| 2018 | 45 | 77 |
| 2019 | 58 | 86 |
| 2020 | 65 | 91 |
| 2021 | 45 | 100 |
| 2022 | 35 | 81 |
| 2023 | 37 | 83 |
| 2024 | 29 | 75 |
| 2025 | 48 | 67 |
| 2026 | 17 | 71 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for preventing skin toxicities caused by biological targeted cancer drugs29 Sep 2026US 12,746,219 B2Hadasit Medical Research Services and Development Ltd.
- Use of phthalide compounds in treatment of meningioma22 Sep 2026US 12,740,964 B2Everfront Biotech Inc.
- Drug coated balloon1 Sep 2026US 12,721,977 B2Medtronic Vascular, Inc.
- Combination cancer therapy using CHK inhibitor25 Aug 2026US 12,714,707 B2Shanghai Huayu Biotechnology Co. Ltd
- RXFP1 agonists18 Aug 2026US 12,709,594 B2Bristol-Myers Squibb Company
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
- (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease8 Oct 2026US 2026/0306503 A1Global Blood Therapeutics, Inc.
- Novel carboxamide derivatives8 Oct 2026US 2026/0308149 A1Angelini Pharma S.P.A.
- Methods and Compositions for Treating Cancer24 Sep 2026US 2026/0284052 A1The United States Government as represented by the Department of Veterans Affairs
- Treatment of cancer with a parg inhibitor17 Sep 2026US 2026/0272936 A1858 Therapeutics, Inc.
Most cited
By later US patents
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Therapeutic inhibitor of vascular smooth muscle cells245US 6,171,609 B2NeoRx Corporation · 2001
- Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier222US 5,853,746 A1998
- Therapeutic inhibitor of vascular smooth muscle cells179US 6,306,421 B1NeoRx Corporation · 2001
- Therapeutic inhibitor of vascular smooth muscle cells171US 6,515,009 B1NeoRx Corporation · 2003